Pinkerton C A, Slack J D, Orr C M, Vantassel J W, Smith M L
Indiana Heart Institute, St. Vincent Hospital and Health Care Center, Indianapolis 46260.
Am J Cardiol. 1988 May 9;61(14):15G-22G. doi: 10.1016/s0002-9149(88)80027-4.
Direct myocardial revascularization surgery using either the saphenous vein or internal mammary artery has become the definitive surgical treatment for coronary artery occlusive disease. Certain patients who have undergone these procedures, however, have recurrent myocardial ischemia due to progression of disease in unbypassed vessels, to obstruction in the arteries distal to the insertion of the bypass conduit, or to disease of the conduit itself. Balloon angioplasty may be used to relieve myocardial ischemia in these situations; however, initial studies suggested a low primary success rate coupled with excessive mortality and morbidity. Improvements in patient selection, equipment and technical expertise now allow angioplasty to be performed in this patient population with results comparable to that in the general coronary angioplasty population. Of the 3,016 angioplasty procedures performed between September 1980 and June 1987, 236 patients had previously undergone revascularization surgery. The primary success rate was 93% (390 of 419 stenoses successfully dilated). Overall, clinical restenosis was observed in 39%, including a 43% restenosis rate in patients undergoing only saphenous vein graft angioplasty. This did not differ appreciably from the restenosis rate in postbypass patients undergoing angioplasty of only native vessels (37%) or internal mammary arteries (42%). Emergency revascularization surgery was required in 7 of 236 patients (3%), each of whom had myocardial infarction. One of 236 patients (0.4%) died. Thus, angioplasty may be used to relieve recurrent myocardial ischemia in patients with prior direct myocardial revascularization procedures with a high initial success rate and acceptable risk. Early (less than 6 months) restenosis is not infrequent and remains the largest obstacle to a satisfactory clinical outcome.(ABSTRACT TRUNCATED AT 250 WORDS)
使用大隐静脉或乳内动脉进行直接心肌血运重建手术已成为冠状动脉闭塞性疾病的确定性手术治疗方法。然而,某些接受过这些手术的患者会因未搭桥血管的疾病进展、搭桥导管插入远端动脉的阻塞或导管本身的疾病而出现复发性心肌缺血。在这些情况下,可使用球囊血管成形术来缓解心肌缺血;然而,初步研究表明其初始成功率较低,且死亡率和发病率过高。如今,患者选择、设备及技术专长方面的改进使得血管成形术能够在这类患者群体中开展,其结果与一般冠状动脉血管成形术人群相当。在1980年9月至1987年6月期间进行的3016例血管成形术手术中,有236例患者此前接受过血运重建手术。初始成功率为93%(419处狭窄中有390处成功扩张)。总体而言,临床再狭窄发生率为39%,仅接受大隐静脉移植血管成形术的患者再狭窄率为43%。这与仅对自身血管(37%)或乳内动脉(42%)进行血管成形术的搭桥术后患者的再狭窄率并无明显差异。236例患者中有7例(3%)需要进行急诊血运重建手术,他们均发生了心肌梗死。236例患者中有1例(0.4%)死亡。因此,血管成形术可用于缓解既往接受过直接心肌血运重建手术患者的复发性心肌缺血,初始成功率高且风险可接受。早期(不到6个月)再狭窄并不少见,仍然是获得满意临床结果的最大障碍。(摘要截短至250字)